Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 3/20 | 0.48 |
| ▸ | SMPD3 | Q9NY59 | 1/20 | 0.46 |
| ▸ | SCN2A | Q99250 | 7/20 | 0.44 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.37 |
| ▸ | TDO2 | P48775 | 2/20 | 0.37 |
| ▸ | TNKS | O95271 | 1/20 | 0.36 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.36 |
| ▸ | PARP2 | Q9UGN5 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046378 | 0.77 | TDO2 (0.39) | HPGDSPDE10AIDO1TDO2 | |
| SCHEMBL10046381 | 0.72 | KDR (0.34) | PDE10A | |
| SCHEMBL10046380 | 0.71 | NPC1 (0.34) | — | |
| SCHEMBL10046382 | 0.71 | PDE10A (0.37) | PDE10AIDO1TDO2 | |
| SCHEMBL13074827 | 0.71 | HPGDS (0.44) | HPGDSSMPD3SCN2ANPY5RRECQL | |
| SCHEMBL10046376 | 0.70 | PDGFRB (0.38) | PDE10A | |
| SCHEMBL30406553 | 0.66 | SCN2A (0.61) | HPGDSSMPD3SCN2ANPY5RRECQL | |
| SCHEMBL2842992 | 0.66 | HPGDS (1.00) | HPGDSSMPD3SCN2ANPY5RRECQL | |
| SCHEMBL9892707 | 0.65 | CYP19A1 (0.39) | PDE10AIDO1TDO2 | |
| SCHEMBL22291104 | 0.63 | SMPD3 (1.00) | HPGDSSMPD3SCN2ANPY5RRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165534-A1 | PROCESS FOR PREPARING BROMO-SUBSTITUTED QUINOLINES | HCCS, CYP3A7, ABL1 | HPGDS 2246/4885SMPD3 3450/4885SCN2A 2986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.